C O N T I N U I N G E D U C A T I O N C O N F E R E N C E B Y T H E U N I V E R S I T Y O F T E X A S A T A U S T I N C O L L E G E O F P H A R M A C Y Agendaasof10.2.17SubjecttoChangeGB

29th ANNUAL

PSYCHIATRIC PHARMACOTHERAPY UPDATE OCTOBER 19 & 20, 2017 • AUSTIN, TEXAS

DAYI•THURSDAY,19thOFOCTOBER2017•DRAFT7:00 CONTINENTALBREAKFAST BallroomLobby

7:45 WelcomeandOpeningRemarks AllpresentationstakeplaceintheBallroom

8:00

UnconsciousBias

ReneSalazar,M.D.AssistantDeanforDiversityandProfessorofMedicalEducationTheUniversityofTexasDellMedicalSchool

• Summarizethestateofthescienceonunconsciousbias• Recognizetheimpactofunconsciousbiasonhealthcaredisparities• Describeseveralstrategiestomitigatetheimpactofunconscious

biasonhealthcaredisparitiesE0067-0000-17-076-L04-P

9:15

PsychopharmacologicTreatmentofPTSD

KimberlyArlinghaus,M.D.PsychiatristCedarParkPsychiatry

• Discussevidence-based,psychopharmacologictreatmentsforindividualswithPTSD.

• Discussnon-pharmacologictreatmentmodalitiesincludingevidence-basedpsychotherapies,psychosocialinterventions,andintegrative,holisticapproachestoPTSD.

• RecallnewtreatmentstrategiesforPTSDthatutilizenovelmethods,technology,anddeliverysystems.0067-0000-17-077-L01-P

10:15 BREAK RefreshmentsinBallroomLobby

10:30

PsychotropicNewDrugUpdate

StephenR.Saklad,Pharm.D.,BCPPClinicalAssociateProfessorTheUniversityofTexasatAustinCollegeofPharmacy

• Describethepharmacology,adverseeffects,druginteractions,therapeuticuses,anddosingofselectedpsychiatricdrugsrecentlymarketedaswellasdrugsapproachingthemarket.

• Reviewpharmacology,adverseeffects,druginteractions,therapeuticuses,anddosingofselectedpsychiatricdrugsthathavebeenreleasedinthepastfiveyears.

0067-0000-17-078-L01-P

12:00 LUNCH BuffetinBallroomLobby

1:00

TreatmentRefractorySchizophrenia

TroyA.Moore,Pharm.D.,M.S.Pharm.,BCPPClinicalPharmacySpecialist–PsychiatryDirector,ASHP-AccreditedPGY-2PsychiatricPharmacyResidencyProgramCo-Director,InterprofessionalAdvancedFellowshipinAddictionTreatmentSouthTexasVeteransHealthCareSystem

• Describeevidenceforvarioustreatmentoptionsforrefractoryschizophrenia,includingsupportontheuseofantipsychoticpolypharmacy.

• Discussrecenttrendsintreatmentforrefractoryschizophrenia.0067-0000-17-079-L01-P

2:00

InterdisciplinaryApproachestoTreatingChronicPain

ShuangOuyang,Pharm.D.PainClinicalPharmacySpecialistSouthTexasVeteransHealthCareSystem

• Discussinterdisciplinaryapproachestotreatingchronicpaininrelationtomentalhealthpatients.

• Discussrecentstudiesonpaintreatmentoutcomes.• Discussethicsissuesinregardstouseofpainmedication,opioid

abuse,andrelationtoillegalsubstitutes.E0067-0000-17-080-L01-P

3:00 BREAK RefreshmentsinBallroomLobby

3:15

ManagementofAnxietyandBipolarinGeriatricPatients

EricaGarcia-Pittman,M.D.AssistantProfessorofPsychiatryTheUniversityofTexasDellMedicalSchool

• Discussrisks/issueswiththeuseofantidepressantstheintreatmentofanxiety/bipolardisorderingeriatricpatients.

• Discusscurrenttrendsandliteratureregardingthemanagementofanxietyandbipolardisorderinthegeriatricpopulation.

• Reviewguidelinesforuseoftraditionalmoodstabilizersinolderadultsincludingmonitoringrecommendations

0067-0000-17-081-L01-P

4:15

SmokingCessationinMentalIllness

CynthiaGutierrez,Pharm.D.,M.S.,BCPPClinicalPharmacyProgramManager,MentalHealthClinicalPharmacySpecialist,PsychiatrySouthTexasVeteransHealthCareSystem

• Discusstreatmentapproachesforsmokingcessationinmentalhealthpatients.

• DiscussrecentrevisionsmadebytheFDAtotheproductlabelingofChantix(R)(varenicline).

• Discusethicalissuesinrelationtothetreatmentornon-treatmentofsmokingcessationinmentalhealthpatients.

0067-0000-17-082-L01-P

5:15 NETWORKINGRECEPTION Dover’sRoom

C O N T I N U I N G E D U C A T I O N C O N F E R E N C E B Y T H E U N I V E R S I T Y O F T E X A S A T A U S T I N C O L L E G E O F P H A R M A C Y Agendaasof10.2.17SubjecttoChangeGB

29th ANNUAL

PSYCHIATRIC PHARMACOTHERAPY UPDATE OCTOBER 19 & 20, 2017 • AUSTIN, TEXAS

DAYII•FRIDAY20thOFOCTOBER2017•DRAFT CONTINENTALBREAKFAST BallroomLobby

7:45 WelcomeandAnnouncements AllpresentationstakeplaceintheBallroom

8:00

AnticholinergicUseintheMentalHealthPopulation

RyanM.Carnahan,Pharm.D.AssociateProfessorofEpidemiologyTheUniversityofIowaCollegeofPublicHealth

• Discusstherisksandbenefitsofanticholinergicuseintheelderly• Reviewanticholinergicburdenofvariousagents• Discussstudiesshowingpossibleincreasedriskforneurocognitive

disorders,particularlywithlong-termuseofanticholinergics0067-0000-17-083-L01-P

9:00

ImpulseControlinChildrenandAdolescents:DiagnosticChallengesandTreatmentOptions

JulieA.Dopheide,Pharm.D.Professor,DirectorofContinuingProfessionalDevelopment,DirectorofPGY2PsychiatricPharmacyResidencyUniversityofSouthernCaliforniaSchoolofPharmacy

• Differentiatebetweenthevaryingpresentationsofimpulsivityinyouthwithattention-deficithyperactivitydisorder(ADHD),bipolardisorder(BD),disruptivemooddysregulationdisorder(DMDD)andautismspectrumdisorder(ASD).

• Describeevidence-basedtreatmentoptionsforimpulsivitybasedontheprimarymentalhealthdiagnosis.

• Discussspecificpatientcasesandrecommendappropriatetreatmentforthepresentingimpulsecontroldisorder.

0067-0000-17-084-L01-P

10:00 BREAK RefreshmentsinBallroomLobby

10:15

AnEvidenceBasedApproachtothePharmacotherapyofMoodDisordersinChildrenandAdolescents

M.LynnCrismon,Pharm.D.,BCPPDeanandCentennialProfessorofHealthOutcomesandPharmacyPracticeTheUniversityofTexasatAustinCollegeofPharmacy

• Discussthegeneralprinciplesforuseofpsychotropicmedicationinchildren.

• Identifynewparametersthatindicatemedicationtreatmentneedstobefurtherevaluatedforappropriateness.

• Identifypotentialethicalcontroversiesthatneedtobeaddressedwhenusingpsychotropicmedicationsinyouth.

E0067-0000-17-085-L01-P

11:15

SubstanceAbuseUpdate

CarlosTirado,M.D.,M.P.H.ChiefMedicalOfficerCARMAHealth

• Discusstrendsandtreatmentsofsubstanceabuse.• Discussethicalissuespractitionersfaceindealingwithnewtrendsin

substanceabuseintheirmentalhealthpopulation.E0067-0000-17-086-L01-P

12:15 WORKINGLUNCH PickuplunchinLobbyandreturntoclassroom

12:30

PreventingGunViolenceandSuicideattheIntersectionwithMentalIllness:APublicHealthLawPerspective

JeffreySwanson,Ph.D.ProfessorandAssociateDirector,DivisionofSocialandCommunityPsychiatry,DepartmentofPsychiatryandBehavioralSciencesDukeUniversitySchoolofMedicine

• Describethenatureandscopeoftheproblemoffirearm-relatedviolenceandsuicideintheUSfromapublichealthperspective,andplacetheproblemincontextwithinternationalcomparisons.

• Describecurrentevidenceforthelinkbetweenseriousmentalillnessandfirearm-relatedinjuryandmortality,withinthecontextofthesocialenvironmentandthemultiplefactorsthatcontributetogunviolenceandsuicide.

E0067-0000-17-087-L01-P

1:45 BREAK RefreshmentsinBallroomLobby

2:00

USP800:ImpactonHandlingHazardousPsychotropicDrugs

AnnRichards,Pharm.D.PCPPPharmacyDirectorSanAntonioStateHospital

• UnderstandinghowUSP800willaffectyourpsychiatricpractice.• Identifydrugsthatareconsideredtobehazardous.• Identifyappropriateprocessesforhandlinghazardousdrugs.• Developassessmentofriskandethicalissuesaddressedin

managementandhandlingforhazardousdrugs.0067-0000-17-088-L01-P

3:00

ManagingBreakthroughSymptomsinPatientswithSchizophreniaCurrentlyTreatedwithLong-ActingInjectable(LAI)Antipsychotics

StephenR.Saklad,Pharm.D.,BCPPClinicalAssociateProfessorTheUniversityofTexasatAustinCollegeofPharmacy

• Discusstheprocessofconsideringcontributingfactorsincludingmedicalillness,substanceabuse/misuse,stressors,andoptimizingnonpharmacologictreatments

• ExplainproperLAIadministrationtechniqueandhowtoaddressmissedorlateLAIdoses

• CompareincreasingLAIdose,shorteningLAIinjectioninterval,andsupplementingtheLAIwithalowdoseofthecorrespondingoralformulation0067-0000-17-089-L01-P

4:00 CEEVALUATION/CLOSING

E denotesCMEandSocialWorkEthicscredit.SeefullCEcreditinformation:http://sites.utexas.edu/cpe-ppu/ce-credits/